Benefits
Dry eye / tear secretion improvement (Riva 2017)
Randomized, double-blind, placebo-controlled trial in 21 subjects with dry eye. 160 mg/day Mirtoselect for 4 weeks improved Schirmer's test scores (tear secretion volume): +71% in right eye (p=0.009), +55% combined (p=0.019) vs placebo. Published in European Review for Medical and Pharmacological Sciences. Mechanism: improved vascular circulation to lacrimal gland.
Intraocular pressure reduction (Mirtogenol combination)
Steigerwalt 2008 trial: 20 asymptomatic patients with elevated intraocular pressure (24-26 mmHg, not on medication) given Mirtogenol® (160 mg Mirtoselect + 80 mg Pycnogenol) twice daily for 6 months. 19 of 20 patients reached normal IOP by 2 months. 13% IOP reduction overall vs no change in control. Useful for ocular hypertension and glaucoma prevention contexts.
Vascular health and microcirculation
Anthocyanins improve capillary integrity and reduce vascular permeability. Multiple trials show Mirtoselect at 160-320 mg/day improves symptoms of chronic venous insufficiency (leg heaviness, swelling, varicose vein symptoms). Foundation use case for bilberry dating back to its WWII reputation among RAF pilots for night vision.
Anthocyanin profile and authenticity
Mirtoselect's HPLC fingerprint distinguishes authentic Vaccinium myrtillus (true bilberry) from cheaper substitutes (blueberry, lingonberry, mulberry). The anthocyanin profile includes 15 distinct glycosides — useful for authentication and quality control. Many cheap 'bilberry' supplements contain adulterants undetectable without HPLC fingerprinting.
Antioxidant and oxidative stress reduction
Anthocyanins have well-documented antioxidant activity, particularly relevant to retinal tissues where oxidative stress drives age-related macular degeneration. The Riva 2017 trial documented improvements in oxidative stress biomarkers alongside the dry eye outcomes.
Non-anthocyanin component synergy
Gizzi 2016 preclinical research suggests the non-anthocyanin components of Mirtoselect (phenolic acids, vitamin C, minerals from the whole-fruit matrix) may contribute to bioavailability and biological activity — supporting the whole-fruit extract approach vs purified anthocyanin isolates. Plasma anthocyanin AUC was higher with Mirtoselect than with a higher-dose purified anthocyanin extract in rats.
Mechanism of action
Capillary integrity and microcirculation
Anthocyanins strengthen capillary walls, reduce vascular permeability, and improve red blood cell deformability — collectively improving microcirculation in small vessels including those of the retina, eye, and lower extremities. This is the dominant mechanism for bilberry's eye and venous insufficiency applications.
Antioxidant activity in ocular tissues
Anthocyanins are potent free radical scavengers that accumulate in ocular tissues. The retina has unusually high oxygen demand and oxidative stress; anthocyanin antioxidant effects may be more biologically relevant in the eye than in many other organs.
Rhodopsin regeneration support
Bilberry's traditional reputation for night vision support is mechanistically linked to anthocyanin effects on rhodopsin regeneration in rod photoreceptors. Modern evidence for acute night vision improvement is mixed, but the biochemical mechanism is real.
Anti-inflammatory effects on vascular endothelium
Anthocyanins inhibit pro-inflammatory cytokine release from vascular endothelium and reduce expression of adhesion molecules (VCAM-1, ICAM-1) — complementing the structural capillary effects with anti-inflammatory endothelial modulation.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 21 subjects experiencing dry eye. Intervention: 160 mg/day Mirtoselect (2 tablets × 80 mg) or placebo for 4 weeks. Outcome: significantly improved Schirmer's test values — +71% in right eye (p=0.009) and +55% combined (p=0.019) vs placebo. Antioxidant biomarkers also improved. Published in European Review for Medical and Pharmacological Sciences. First clinical evidence for bilberry in dry eye.
Open-label controlled trial in 38 asymptomatic patients with elevated intraocular pressure (24-26 mmHg, not on glaucoma medication). 20 patients received Mirtogenol® (160 mg Mirtoselect + 80 mg Pycnogenol) twice daily for 6 months; 18 patients control. 19 of 20 patients in the Mirtogenol group reached normal IOP by 2 months. Overall 13% IOP reduction vs no change in control. Increased ophthalmic artery blood flow velocity also documented.